Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.The Journal of clinical endocrinology and metabolism · 2020
   Guideline
2. Punicalagin alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via NRF2/HO-1 pathway.Regenerative therapy · 2026
   Article
3. Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis.Breast (Edinburgh, Scotland) · 2026
   Article
4. A Multidisciplinary Approach to Addressing Barriers in Osteoporosis Screening, Diagnosis, Therapy Sequencing, and Adherence in India.Cureus · 2026
   Review
5. Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment.Journal of bone and mineral metabolism · 2026
   Article
6. Early Denosumab Administration after Distal Radius Fractures in Postmenopausal Women: A Retrospective Comparison with Zoledronic Acid.Clinics in orthopedic surgery · 2026
   Article
7. N6-Methyladenosine Modification of the Three Components "Writers", "Erasers", and "Readers" in Relation to Osteogenesis.International journal of molecular sciences · 2025
   Review
8. Global current research status and future hotspots in osteoporotic fracture based on bibliometric assessment and visualization techniques.World journal of clinical cases · 2024
   Article
9. Long-term consequences of osteoporosis therapy with bisphosphonates.Archives of endocrinology and metabolism · 2023
   Review
10. Osteoporosis and Fracture Risk among Older US Asian Adults.Current osteoporosis reports · 2023
    Review
11. Advances in the study of traditional Chinese medicine affecting bone metabolism through modulation of oxidative stress.Frontiers in pharmacology · 2023
    Review
12. The role of the fracture liaison service in the prevention of atypical femoral fractures.Therapeutic advances in musculoskeletal disease · 2023
    Review
13. Controversies in Osteoporosis Treatment of Nursing Home Residents.Journal of the American Medical Directors Association · 2022
    Review
14. The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance.Nutrients · 2022
    Review
15. Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p.Bioengineered · 2022
    Article
16. Plate osteosynthesis for atypical femoral fractures in patients with severely bowed femurs: comparing short versus long segment fixation - a case series.International journal of burns and trauma · 2022
    Review
17. Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.Frontiers in pharmacology · 2022
    Article
18. Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway.Frontiers in pharmacology · 2022
    Article
19. Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis.Bioactive materials · 2021
    Article
20. Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?JBMR plus · 2021
    Article

Corrections and comments

• Erratum for
  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.2016

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.